Nothing Special   »   [go: up one dir, main page]

BR112012022939A2 - composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza - Google Patents

composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza

Info

Publication number
BR112012022939A2
BR112012022939A2 BR112012022939A BR112012022939A BR112012022939A2 BR 112012022939 A2 BR112012022939 A2 BR 112012022939A2 BR 112012022939 A BR112012022939 A BR 112012022939A BR 112012022939 A BR112012022939 A BR 112012022939A BR 112012022939 A2 BR112012022939 A2 BR 112012022939A2
Authority
BR
Brazil
Prior art keywords
influenza virus
immunizing
individual
need
pharmaceutical composition
Prior art date
Application number
BR112012022939A
Other languages
English (en)
Inventor
Christopher H Clegg
Neal Van Hoeven
Steven G Reed
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Design Corp filed Critical Immune Design Corp
Publication of BR112012022939A2 publication Critical patent/BR112012022939A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

vacinas para influenza pandêmica. composições de vacina e farmacêuticas compreendem hemaglutinina recombinante de um vírus influenza pandêmico ou pré-pandêmico e um adjuvante compreendendo gla. um vírus influenza pré-pandêmico particularmente relevante é h5n1. kits e métodos de utilizar as composições também são fornecidos.
BR112012022939A 2010-03-11 2011-03-10 composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza BR112012022939A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31310110P 2010-03-11 2010-03-11
PCT/US2011/027993 WO2011112871A1 (en) 2010-03-11 2011-03-10 Vaccines for pandemic influenza

Publications (1)

Publication Number Publication Date
BR112012022939A2 true BR112012022939A2 (pt) 2016-08-02

Family

ID=44170437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022939A BR112012022939A2 (pt) 2010-03-11 2011-03-10 composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza

Country Status (13)

Country Link
US (1) US20110305748A1 (pt)
EP (1) EP2544718A1 (pt)
JP (2) JP2013522231A (pt)
KR (1) KR20130048208A (pt)
CN (1) CN102946900A (pt)
AU (1) AU2011224245B2 (pt)
BR (1) BR112012022939A2 (pt)
CA (1) CA2792369A1 (pt)
EA (1) EA201290897A1 (pt)
MX (1) MX2012010472A (pt)
NZ (1) NZ602217A (pt)
SG (1) SG183514A1 (pt)
WO (1) WO2011112871A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PT2811981T (pt) * 2012-02-07 2019-06-12 Infectious Disease Res Inst Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
JP5944210B2 (ja) * 2012-04-18 2016-07-05 一般財団法人化学及血清療法研究所 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子が組み込まれたｂ５ｒ遺伝子欠損組換えワクシニアウイルス
JP2016532712A (ja) * 2013-09-05 2016-10-20 イミューン デザイン コーポレイション 薬物中毒に対するワクチン組成物
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN111375055B (zh) * 2020-02-20 2021-09-03 陈宛莎 一种2019-nCoV亚单位疫苗组合物及其免疫方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3581722D1 (de) 1984-07-20 1991-03-14 Celltech Ltd Eukaryotische expressionsvektoren.
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69015222T2 (de) 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
US6022726A (en) 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
EP0651656A1 (en) 1992-07-08 1995-05-10 Schering Corporation Use of gm-csf as a vaccine adjuvant
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
DE9319879U1 (de) 1993-12-23 1994-03-17 Ems-Inventa AG, Zürich Sequentiell Coextrudierte Kühlflüssigkeitsleitung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
GB9809666D0 (en) 1998-05-06 1998-07-01 Isis Innovation Modified viruses
DK1075276T3 (da) 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005116270A2 (en) 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use
DK2497492T3 (en) 2004-06-01 2018-11-26 Icahn School Med Mount Sinai Genetically modified swine influenza virus and its applications
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
PL2043682T3 (pl) * 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2822058T3 (es) * 2006-09-26 2021-04-28 Infectious Disease Res Inst Composición de vacuna que contiene un adyuvante sintético
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
JP2007314538A (ja) * 2007-05-23 2007-12-06 Protein Sciences インフルエンザ血球凝集素多価ワクチンの製造方法
CA2698668A1 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
WO2009092038A1 (en) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos

Also Published As

Publication number Publication date
MX2012010472A (es) 2012-11-30
JP2013522231A (ja) 2013-06-13
WO2011112871A1 (en) 2011-09-15
EP2544718A1 (en) 2013-01-16
SG183514A1 (en) 2012-10-30
CN102946900A (zh) 2013-02-27
JP2016104815A (ja) 2016-06-09
CA2792369A1 (en) 2011-09-15
AU2011224245A1 (en) 2012-09-27
AU2011224245B2 (en) 2014-12-04
NZ602217A (en) 2014-08-29
EA201290897A1 (ru) 2013-03-29
KR20130048208A (ko) 2013-05-09
US20110305748A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
BR112012022939A2 (pt) composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
EP4233898A3 (en) Influenza mrna vaccines
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
IN2014CN02114A (pt)
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
MX2018004916A (es) Vacuna contra el virus de la influenza de amplio espectro.
BR112013020743A2 (pt) composições e métodos para a terapia e diagnóstico de influenza
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
BR112015012841A2 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
EA201391515A1 (ru) Инактивированная вакцина вируса денге
BR112013031505A2 (pt) "polipeptídeo, uso de um polipeptídeo, molécula de ácido nucleico, vetor, hospedeiro, formulações de vacina e usos de uma formulação de vacina
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
PE20151588A1 (es) Vacuna contra el virus del dengue
AU2011280259A8 (en) Influenza vaccine
BR112013030395A2 (pt) polipeptídeo, polinucleotídeo, vetor, composição imunogênica, vacina, e, uso de uma composição imunogênica
AR080111A1 (es) Metodos y composiciones de inmunizacion
WO2015195218A8 (en) Polyvalent influenza virus-like particles (vlps) and use as vaccines
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
BR112012030619A2 (pt) concentração de antígenos de vacina influenza sem liofilização.
EA201400235A1 (ru) Вакцины против гриппа на основе н5
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
AU2015364253B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
RU2014140168A (ru) Улучшенная вакцинация против гриппа

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2506 DE 15/01/2019.